Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.59 |
| ▸ | GUSB | P08236 | 4/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252809 | 0.92 | DGAT1 (0.62) | DGAT1GUSBSIRT2SIRT1SIRT3 | |
| SCHEMBL31326544 | 0.91 | DGAT1 (0.63) | DGAT1GUSBSIRT2SIRT1SIRT3 | |
| SCHEMBL1252723 | 0.91 | DGAT1 (0.63) | DGAT1GUSBSIRT2SIRT1SIRT3 | |
| SCHEMBL1252108 | 0.82 | DGAT1 (0.65) | DGAT1GUSBSIRT2SIRT1SIRT3 | |
| SCHEMBL1252728 | 0.81 | DGAT1 (0.59) | DGAT1SIRT2SIRT1SIRT3CHEK2 | |
| SCHEMBL1250496 | 0.79 | DGAT1 (0.80) | DGAT1GUSBSIRT2SIRT1SIRT3 | |
| SCHEMBL1252747 | 0.79 | DGAT1 (0.85) | DGAT1GUSBMAPTKDRPOLB | |
| SCHEMBL1252721 | 0.79 | DGAT1 (0.79) | DGAT1GUSBMAPTKDM4EALDH1A1 | |
| SCHEMBL10299681 | 0.78 | DGAT1 (0.81) | DGAT1GUSBSIRT2SIRT1SIRT3 | |
| SCHEMBL1250566 | 0.77 | DGAT1 (0.63) | DGAT1MAPTPOLBTP53CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-20110077277-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077277-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GUSB 217/4885SIRT2 2280/4885 |
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GUSB 217/4885SIRT2 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.